AMLODIPINE FORMULATIONS

1 - 30 . (canceled)

31 . An oral liquid formulation comprises:

(i) amlodipine benzoate in an amount corresponding to 1.0 mg/ml amlodipine freebase;

(ii) 0.2 mg/ml to 10 mg/ml of sodium benzoate;

(iii) a suspension aid comprising silicon dioxide, hydroxypropyl methylcellulose, methylcellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, polyvinylpyrrolidone, xanthan gum, or any combination thereof;

(iv) a non-ionic surfactant that is present at about 0.1 mg/ml to about 3.0 mg/ml in the oral liquid formulation;

(v) optionally one or more selected from a buffer, a flavoring agent, a sweetener, a preservative; and

(vi) water;

wherein the oral liquid formulation is stable at 5±5° C. for a storage period of at least 12 months; and wherein the stable oral liquid formulation has 95% w/w or greater of the initial amlodipine amount and 5% w/w or less total impurities or related substances at the end of the given storage period.

32 . The formulation of claim 31 , wherein the suspension aid is present in the oral liquid formulation at 5.0 mg/ml to 15.0 mg/ml.

33 . The formulation of claim 32 , wherein the suspension aid is present in the oral liquid formulation at 3.0 mg/ml to 10.0 mg/ml.

34 . The formulation of claim 31 , wherein the suspension aid comprises silicon dioxide, hydroxypropyl methylcellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, or any combination thereof.

35 . The formulation of claim 31 , wherein the suspension aid comprises silicon dioxide and hydroxypropyl methylcellulose.

36 . The formulation of claim 31 , wherein the non-ionic surfactant is present at about 1.0 mg/ml in the oral liquid formulation.

37 . The formulation of claim 31 , wherein the non-ionic surfactant is polyoxyethylene glycol sorbitan alkyl ester.

38 . The formulation of claim 37 , wherein the polyoxyethylene glycol sorbitan alkyl ester is polysorbate 20 or polysorbate 80.

39 . The formulation of claim 31 , wherein the non-ionic surfactant is a block copolymers of polyethylene glycol and polypropylene glycol, a polyethylene glycol octylphenyl ether, polyethylene glycol alkyl ether, or any combination thereof.

40 . The formulation of claim 31 , wherein the pH is between 4 and 6.

41 . The formulation of claim 31 , wherein the oral liquid formulation comprises a buffer.

42 . The formulation of claim 41 , wherein the buffer is present at 0.1 mg/ml to about 1.0 mg/ml in the oral liquid formulation.

43 . The formulation of claim 41 , wherein the buffer comprises a citrate buffer, a phosphate buffer, an acetate buffer, or any combination thereof.

44 . The formulation of claim 43 , wherein the citrate buffer comprises critic acid and sodium citrate.

45 . The formulation of claim 31 , wherein the oral liquid formulation comprises a sweetener.

46 . The formulation of claim 45 , wherein the sweetener is present in about 0.5 mg/ml to about 0.9 mg/ml in the oral liquid formulation.

47 . The formulation of claim 45 , wherein the sweetener comprises glucose, fructose, sucrose, xylitol, tagatose, sucralose, maltitol, isomaltulose, hydrogenated isomaltulose, lactitol, sorbitol, erythritol, trehalose, maltodextrin, or any combination thereof.

48 . The formulation of claim 47 , wherein the sweetener is sucralose.

49 . The formulation of claim 31 , wherein the oral liquid formulation comprises a flavoring agent.

50 . The formulation of claim 31 , wherein the oral liquid formulation is in the form of a suspension.